اخبار و اعلانات

 آمار

تعداد نشریات287
تعداد نشریات سازمان85
تعداد شماره‌ها3,159
تعداد مقالات35,108
تعداد مشاهده مقاله50,526,978
تعداد دریافت فایل اصل مقاله90,476,656
Madani, Rasool, Golchinfar, Fariba, Hezarosi, Mahsa. (1404). Monoclonal Antibodies in Modern Medicine and laboratory: A comprehensive review. سامانه مدیریت نشریات علمی, 80(Special Issue), 11-19. doi: 10.32592/ARI.2025.80.SpecialIssue.11
Rasool Madani; Fariba Golchinfar; Mahsa Hezarosi. "Monoclonal Antibodies in Modern Medicine and laboratory: A comprehensive review". سامانه مدیریت نشریات علمی, 80, Special Issue, 1404, 11-19. doi: 10.32592/ARI.2025.80.SpecialIssue.11
Madani, Rasool, Golchinfar, Fariba, Hezarosi, Mahsa. (1404). 'Monoclonal Antibodies in Modern Medicine and laboratory: A comprehensive review', سامانه مدیریت نشریات علمی, 80(Special Issue), pp. 11-19. doi: 10.32592/ARI.2025.80.SpecialIssue.11
Madani, Rasool, Golchinfar, Fariba, Hezarosi, Mahsa. Monoclonal Antibodies in Modern Medicine and laboratory: A comprehensive review. سامانه مدیریت نشریات علمی, 1404; 80(Special Issue): 11-19. doi: 10.32592/ARI.2025.80.SpecialIssue.11

Monoclonal Antibodies in Modern Medicine and laboratory: A comprehensive review

Archives of Razi Institute
مقاله 2، دوره 80، Special Issue - شماره پیاپی 1، 2025، صفحه 11-19    اصل مقاله (256.18 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.32592/ARI.2025.80.SpecialIssue.11
نویسندگان
Rasool Madani* ؛ Fariba Golchinfar؛ Mahsa Hezarosi
Department of Proteomics and Biochemistry, Razi vaccine and serum research institute, Agricultural research education and extension organization (AREEO), Karaj, Iran
چکیده
Monoclonal antibodies (mAbs) are a revolutionary advancement in therapeutic interventions, offering specificity in the treatment of various diseases, including cancers, autoimmune disorders, and infectious diseases. These agents have also changed diagnosis tests, particularly immunoassays which are based on antibodies like ELISA, Immunohistochemistry and Flowcytometry. This review article critically evaluates the development, mechanisms of action, clinical applications of monoclonal antibodies, and their usage in diagnosis. We also explain the process of mAb production, such as hybridoma technology, as well as the emergence of novel formats such as bispecific antibodies and antibody-drug conjugates. Additionally, we analyze the current landscape of mAb therapies in clinical practice and highlight recent FDA approvals and ongoing clinical trials. Challenges such as immunogenicity, production costs, and access to therapy are also discussed. This comprehensive review aims to provide a deep understanding of monoclonal antibodies’ impact on modern medicine and their potential to shape future therapeutic plans. Additionally, this review highlights monoclonal antibody projects in Iran, particularly at the Razi Vaccine and Serum Research Institute. In this institute, monoclonal antibodies have not only been produced but also developed and applied for the first time in Iran in diagnostic tests for human and animal infectious diseases. Therefore, the Razi Vaccine and Serum Research Institute can be considered one of the pioneers in this field, and its advancements may also benefit neighboring developing countries by providing monoclonal antibodies for both therapeutic and diagnostic purposes.
کلیدواژه‌ها
Monoclonal antibodies؛ mechanisms؛ clinical applications؛ future therapeutic paradigms
عنوان مقاله [English]
آنتی بادی های مونوکلونال در پزشکی و آزمایشگاه مدرن: بررسی جامع
چکیده [English]
مونوکلونال آنتی‌بادی‌ها (mAbs) یک پیشرفت انقلابی در مداخلات درمانی به شمار می‌روند و به دلیل ویژگی اختصاصی خود در درمان بیماری‌های مختلف از جمله سرطان‌ها، اختلالات خودایمنی و بیماری‌های عفونی کاربرد دارند. این عوامل همچنین آزمون‌های تشخیصی را متحول کرده‌اند، به‌ویژه ایمنواسی‌هایی که بر پایه آنتی‌بادی‌ها هستند، مانند ELISA، ایمونوهیستوشیمی و فلوسایتومتری. این مقاله مروری به بررسی توسعه، مکانیسم‌های عمل، کاربردهای بالینی مونوکلونال آنتی‌بادی‌ها و استفاده آن‌ها در تشخیص می‌پردازد. همچنین فرآیند تولید mAbها مانند فناوری هیبریدوما و ظهور قالب‌های جدیدی همچون آنتی‌بادی‌های bispecific و کونژوگه‌های آنتی‌بادی-دارو (ADC) توضیح داده می‌شود. علاوه بر این، چشم‌انداز کنونی درمان‌های مبتنی بر mAb در عمل بالینی بررسی شده و به تأییدیه‌های اخیر FDA و کارآزمایی‌های بالینی در حال انجام اشاره شده است. چالش‌هایی همچون ایمنوژنیسیته، هزینه‌های تولید و دسترسی به درمان نیز مورد بحث قرار گرفته‌اند. این مقاله مروری با هدف ارائه درکی عمیق از تأثیر مونوکلونال آنتی‌بادی‌ها بر پزشکی مدرن و پتانسیل آن‌ها در شکل‌دهی برنامه‌های درمانی آینده نگاشته شده است. همچنین، این مقاله به پروژه‌های تولید مونوکلونال آنتی‌بادی در ایران، به‌ویژه در مؤسسه تحقیقات واکسن و سرم‌سازی رازی، می‌پردازد. در این مؤسسه، مونوکلونال آنتی‌بادی‌ها نه تنها تولید شده‌اند، بلکه برای نخستین بار در ایران در آزمون‌های تشخیصی بیماری‌های عفونی انسانی و دامی نیز توسعه یافته و به کار گرفته شده‌اند. بنابراین، مؤسسه تحقیقات واکسن و سرم‌سازی رازی را می‌توان یکی از پیشگامان این حوزه دانست و پیشرفت‌های آن حتی می‌تواند به کشورهای همسایه در حال توسعه نیز سود برساند؛ چرا که این آنتی‌بادی‌ها در زمینه درمان و آزمون‌های تشخیصی بیماری‌های عفونی انسان و دام قابل استفاده‌اند.
کلیدواژه‌ها [English]
آنتی بادی های مونوکلونال, مکانیسم ها, کاربردهای بالینی, مدل های درمانی آینده
مراجع
  1. Lu Y, Zhou N, Huang X, Cheng JW, Li FQ, Wei RL, et al. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. International journal of ophthalmology. 2014;7(1):1-7.
  2. Milstein C, Kohler GJN. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975;256(5517):495-7.
  3. Quinteros DA, Bermúdez JM, Ravetti S, Cid A, Allemandi DA, Palma SD. Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery: Nanostructures for Drug Delivery. 2017:807-33. doi: 10.1016/B978-0-323-46143-6.00025-7. Epub 2017 Mar 31.
  4. Effer B, Perez I, Ulloa D, Mayer C, Muñoz F, Bustos D, et al. Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging. Biomedicines. 2023;11(7)
  5. Mullard A. FDA approves 100th monoclonal antibody product. Nature reviews Drug discovery. 2021;20(7):491-5.
  6. Newsome BW, Ernstoff MS. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? British journal of clinical pharmacology. 2008;66(1):6-19.
  7. Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, et al. Bispecific antibodies: advancing precision oncology. Trends in Cancer. 2024;10(10):893-19
  8. Singh R, Chandley P, Rohatgi S. Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies. ImmunoHorizons. 2023;7(12):886-97.
  9. Surowka M, Klein C. A pivotal decade for bispecific antibodies? mAbs. 2024;16(1):2321635.
  10. Akram F, Ali AM, Akhtar MT, Fatima T, Shabbir I, ul Haq I. The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review. Bioorganic & Medicinal Chemistry. 2025;117:118010.
  11. Osterman MT, Haynes K, Delzell E, Zhang J, Bewtra M, Brensinger C, et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2014;12(5):811-7.e3.
  12. Samaranayake H, Wirth T, Schenkwein D, Räty JK, Ylä-Herttuala S. Challenges in monoclonal antibody-based therapies. Annals of Medicine. 2009;41(5):322-31.
  13. Leavy O. The birth of monoclonal antibodies. Nature Immunology. 2016;17(1):S13-S.
  14. Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-6.
  15. Liddell E. Chapter 3.1 - Antibodies. In: Wild D, editor. The Immunoassay Handbook (Fourth Edition). Oxford: Elsevier; 2013. p. 245-65.
  16. Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and future clinical development. Seminars in Oncology. 2002;29(1, 2):105-12.
  17. Reimold AM. The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. Open Access Rheumatol. 2012;4:33-47.
  18. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002;324(1):14-30.
  19. Sun LK, Curtis P, Rakowicz-Szulczynska E, Ghrayeb J, Chang N, Morrison SL, et al. Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc Natl Acad Sci U S A. 1987;84(1):214-8.
  20. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256-65.
  21. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol. 2008;20(4):450-9.
  22. Tonon G, Rizzolio F, Visentin F, Scattolin T. Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads. International Journal of Molecular Sciences. 2024;25(16):8651.
  23. Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, et al. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40(3):949-82.
  24. Abebe EC, Dejenie TA. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Front Immunol. 2023;14:1055457.
  25. Alejandra W-P, Miriam Irene J-P, Fabio Antonio G-S, Patricia R-GR, Elizabeth T-A, Aleman-Aguilar JP, et al. Production of monoclonal antibodies for therapeutic purposes: A review. International Immunopharmacology. 2023;120:110376.
  26. de St. Groth SF, Scheidegger D. Production of monoclonal antibodies: Strategy and tactics. Journal of Immunological Methods. 1980;35(1):1-21.
  27. Yokoyama WM, Christensen M, Santos GD, Miller D, Ho J, Wu T, et al. Production of Monoclonal Antibodies. Current Protocols in Immunology. 2013;102(1):2.5.1-2.5.29.
  28. Zhao WM, Wang L, Park H, Chhim S, Tanphanich M, Yashiro M, et al. Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res. 2010;16(23):5750-8.
  29. Zahavi D, AlDeghaither D, O'Connell A, Weiner LM. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther. 2018;1(1):7-12.
  30. Golay J, Taylor RP. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies (Basel). 2020;9(4)
  31. Tsao LC, Force J, Hartman ZC. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Res. 2021;81(18):4641-51.
  32. Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies (Basel). 2020;9(3
  33. Masilamani M, Peruzzi G, Borrego F, Coligan JE. Endocytosis and intracellular trafficking of human natural killer cell receptors. Traffic. 2009;10(12):1735-44.
  34. Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress. Nat Rev Drug Discov. 2022;21(9):676-96.
  35. Golchinfar F, Madani R, Emami T. Differentiating pestes des petits ruminants and rinderpest viruses by a novel monoclonal antibody. Hybridoma (2005). 2011;30(3):291-5.
  36. Cicchitto G, Cardillo L, de Martinis C, Sabatini P, Marchitiello R, Abate G, et al. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant. Viruses. 2022;14(3
  37. Vita S, Rosati S, Ascoli Bartoli T, Beccacece A, D'Abramo A, Mariano A, et al. Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature. Pathogens (Basel, Switzerland). 2022;11(8
  38. Wertenauer C, Pfeifer C, Roskos M, März W. Rapid antigen tests for SARS-CoV-2—a synopsis of the medical evidence. Diagnostic Microbiology and Infectious Disease. 2023;107(2):116027.
  39. Hou Y, Nitta H, Parwani AV, Li Z. The assessment of HER2 status and its clinical implication in breast cancer. Diagnostic Histopathology. 2020;26(2):61-8.
  40. Neeli PK, Li Y. 5.06 - Single B-cell sequencing in monoclonal antibody discovery. In: Ramos KS, editor. Comprehensive Precision Medicine (First Edition). Oxford: Elsevier; 2024. p. 73-95.
  41. Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nature reviews Rheumatology. 2020;16(10):565-79.
  42. Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry Part B, Clinical cytometry. 2018;94(1):121-8.
  43. Carrère-Kremer S, Kolia-Diafouka P, Pisoni A, Bolloré K, Peries M, Godreuil S, et al. QuantiFERON-TB Gold Plus Assay in Patients With Latent vs. Active Tuberculosis in a Low Incidence Setting: Level of IFN-γ, CD4/CD8 Responses, and Release of IL-2, IP-10, and MIG. Frontiers in microbiology. 2022;13:825021.
  44. Cerino A, Bremer CM, Glebe D, Mondelli MU. A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity. PloS one. 2015;10(4):e0125704.
  45. Madani R, Golchinfar F, Hezarosi M, Emami T, Ghanizade A. Unleashing Monoclonal Antibodies: Targeting Covid-19’s Nucleocapsid Protein and Spike Antigens. Archives of Razi Institute. 2024.
  46. Madani R, Hezarosi M, Golchinfar F. Unveiling Indirect ELISA Test against Nucleoprotein of H9N2 Comparing With Hemagglutination Inhibition Test. Archives of Razi Institute. 2024;79(4):889-96.
  47. Hashemi M, Madani R, Aghamaali M, Emami T, Golchinfar F. Monoclonal Antibody Preparation Against Nucleoprotein of Avian Influenza Virus Subtype H9N2. Iranian Red Crescent Medical Journal. 2019;21(10
  48. Madani R, Golchinfar,F., Pourbakhsh, S A.,Kianizadeh, M, and Frozandeh Moghadam M. Preparation of Monoclonal Antibody to Fusion Glycoprotein of Newcastle Disease Virus Isolated from Iran. Archives of Razi Institute. 2001;53(1):87-96.
  49. Rahbarizadeh F, Rasaee M, Madani R, Rahbarizadeh M, Omidfar K. Preparation and characterization of specific and high-affinity monoclonal antibodies against morphine. Hybridoma (2005). 2000;19(5):413-7.
  50. Khamehchian S, Madani R, Rasaee MJ, Golchinfar F, Kargar R. Development of 2 types of competitive enzyme-linked immunosorbent assay for detecting antibodies to the rinderpest virus using a monoclonal antibody for a specific region of the hemagglutinin protein. Canadian journal of microbiology. 2007;53(6):720-6.
  51. Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. Journal, genetic engineering & biotechnology. 2021;19(1):159.
  52. Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. 2020;11.
  53. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nature reviews Drug discovery. 2023;22(2):101-26.
آمار
تعداد مشاهده مقاله: 419
تعداد دریافت فایل اصل مقاله: 823


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب